Chromosomal mosaicism goes global
Ivan Y Iourov*¹, Svetlana G Vorsanova² and Yuri B Yurov¹

Address: ¹National Research Center of Mental Health, Russian Academy of Medical Sciences, Moscow, 119152, Russia and ²Institute of Pediatrics and Children Surgery, Rosmedtechnologii, Moscow, 127412, Russia

Email: Ivan Y Iourov* - ivan_iourov@yahoo.com; Svetlana G Vorsanova - svorsanova@mail.ru; Yuri B Yurov - y_yurov@yahoo.com
* Corresponding author

Intercellular differences of chromosomal content in the same individual are defined as chromosomal mosaicism (alias intercellular or somatic genomic variations or, in a number of publications, mosaic aneuploidy). It has long been suggested that this phenomenon poorly contributes both to intercellular (interindividual) diversity and to human disease. However, our views have recently become to change due to a series of communications demonstrated a higher incidence of chromosomal mosaicism in diseased individuals (major psychiatric disorders and autoimmune diseases) as well as depicted chromosomal mosaicism contribution to genetic diversity, the central nervous system development, and aging. The later has been produced by significant achievements in the field of molecular cytogenetics. Recently, Molecular Cytogenetics has published an article by Maj Hulten and colleagues that has provided evidences for chromosomal mosaicism to underlie formation of germline aneuploidy in human female gametes using trisomy 21 (Down syndrome) as a model. Since meiotic aneuploidy is suggested to be the leading genetic cause of human prenatal mortality and postnatal morbidity, these data together with previous findings define chromosomal mosaicism not as a casual finding during cytogenetic analyses but as a more significant biological phenomenon than previously recognized. Finally, the significance of chromosomal mosaicism can be drawn from the fact, that this phenomenon is involved in genetic diversity, normal and abnormal prenatal development, human diseases, aging, and meiotic aneuploidy, the intrinsic cause of which remains, as yet, unknown.

Chromosomal mosaicism was originally defined as the presence of cells differing with respect to their chromosome complement in the same individual [1]. Although chromosomal mosaicism is repeatedly registered during cytogenetic analysis, one of the commonest genetic tests in medical genetics [2], its significance remains usually underappreciated. Nonetheless, during the last decade, a growing amount of studies has demonstrated that chromosomal mosaicism does contribute to human diversity [3-7], diseases [2,4,5,7-12], early prenatal brain development [3,13], and aging [14]. However, the real biomedical meaning of chromosomal mosaicism in humans is hardly known.

One of the previous studies published in Molecular Cytogenetics [15] has brought evidences that chromosomal mosaicism plays a role in the generation of meiotic aneuploidy known to be the leading genetic cause of human prenatal death and congenital malformations/learning disabilities [4,5,16]. Studying chromosome 21 in ovarian cells of normal female foetuses, Prof. Maj Hulten and her colleagues were able to give experimental support for their...
original hypothesis suggesting meiotic aneuploidy in human conceptuses to be the result of ovarian germline mosaicism that is produced during the normal prenatal development [15]. The data fit well with current concepts in biology of aneuploidy, essentially drawn from studies of trisomy 21 (Down's syndrome) [16]. More specifically, these findings have the potential to explain maternal age effect, recurrence of aneuploidy at subsequent conceptions, and abnormal maternal recombination patterns previously found via linkage analyses [15]. Although the idea put forward in this article has revolutionized our thinking about maternal meiotic aneuploidy suggesting mitotic aneuploidy to lie at the origin of meiotic aneuploidy, there was a strong experimental background for this hypothesis. Firstly, it has been recently noticed that chromosomal mosaicism is frequent among human foetuses, achieving the rate of 25% in spontaneous abortions [17]. Additionally, the confinement of chromosomal mosaicism to the specific tissue is a known phenomenon. As early as 1983, Kalousek and Dill have described the existence of chromosomal mosaicism exclusively confined to the placenta (confined placental mosaicism) [18]. About a year ago, there have been shown that somatic chromosomal mosaicism confines to the developing human brain in a significant proportion of normal human conceptions. Furthermore, it has been established that increase of mosaic aneuploidy in the developing human brain is an integral component of the human prenatal central nervous system development [13].

Therefore, one can conclude: (i) chromosomal mosaicism is extremely frequent in human foetuses; (ii) chromosomal mosaicism confines as to extraembryonic tissues (placenta) as to embryonic tissues (central nervous system and ovarian tissue). It is reasonable to suspect, that the latter could be one of the major source for human tissue-specific pathology or multi-system diseases (including those that arise due to meiotic errors), as exemplified by M. Hulten and colleagues [15] as well as previous publications [4,5,7-12,17]. To understand whether chromosomal mosaicism has the potential to mediate intercellular diversity (somatic genome variations in unaffected individuals), one should address studies performed to reveal the real rate of cell-to-cell chromosomal number variability in unaffected human tissues [3-6,13-15,18-24] (Table 1). It is to note that almost all tissues, if thoroughly analyzed by a molecular cytogenetic technique, exhibit aneuploid cells. Thus, we can highlight the major difficulty for studies targeted at revealing effects of chromosomal mosaicism referred to the definition of non-pathogenic level of aneuploidy in a tissue. Therefore, an association between chromosomal mosaicism and an alteration to cellular/tissular physiology requires thorough control study of unaffected individuals (tissues).

Focusing on diseases associated with chromosomal mosaicism, one can note the broad spectrum of pathology associated with this type of somatic genomic variations from cases of chromosomal syndromes to complex neuropsychiatric and immune diseases [2-13,19]. Prof. Hulten and

Table 1: Chromosomal mosaicism in presumably normal human tissues.

| Tissue               | Description                                                                 | References |
|----------------------|-----------------------------------------------------------------------------|------------|
| Ovarian tissues      | Small, but significant proportion of aneuploid cells (trisomy 21) in ovarian tissues of normal female fetuses | [15]       |
|                      | 15–20% of human oocytes                                                    | [19]       |
| Sperm                | 2–10% of spermatozoa (0.1–0.2% per chromosome)                              | [20]       |
| Chorionic villi      | approaching 24% (~1% of aneuploid cells per chromosome)                     | [13]       |
| Fetal human brain    | approaching 30% (~1.5 of aneuploid cells per chromosome)                   | [3,13]     |
|                      | 35% including chromosomal mosaicism confined to the fetal brain            |            |
| Placenta             | No generalized data; chromosomal mosaicism observed in ~2% of foetuses (~9–11 weeks of gestation) referred to prenatal diagnosis | [21]       |
| Skin (adults)        | 2.2% and 4.4% (in young and old individuals, respectively)                  | [22]       |
| Liver (adults)       | ~3%                                                                         | [23]       |
| Blood (adults)       | 1–2% (randomly selected autosomes) and 3% (chromosome X)                   | [24]       |
| Adult human brain    | 0.1–0.7% (autosomes and chromosome Y), 2% (chromosome X); tending to approach 10%, in total | [3,4,6]    |
colleagues [15] have added meiotically originated aneu-
plody syndromes to the "chromosomal mosaicism dis-
ease list". Furthermore, it suggests the commonest genetic
cause of prenatal deaths to arise from chromosomal
mosaicism, as well. Table 2 overviews current knowledge
about chromosomal mosaicism contribution to human
prenatal mortality and postnatal morbidity. We may con-
clude that the confinement of chromosomal mosaicism is
likely to be the reason of tissue-specific dysfunction as
exemplified by brain diseases and fetal brain and ovarian
tissues [4,5,7,8,12,13,15]. Consequently, attempts to
identify the role of chromosomal mosaicism in human
pathology should directly evaluate malfunction tissue.
Unfortunately, due to limited availability of the majority
of human tissues for extended genetic studies and com-
plexity of molecular cytogenetic analyses of low-level ane-
uploidy, such evaluations are rare. To date, only neural
and ovarian tissues were assessed by high-resolution
molecular cytogenetic techniques [3,6,8,12,13,15,25].
Nevertheless, tissues (cell types) more frequently used for
cytogenetic studies (blood lymphocytes, skin fibroblasts,
chorionic villi etc.) can also provide for supporting
hypotheses suggesting chromosomal mosaicism to be a
possible genetic mechanism underlying different human
diseases [4,5,7,10,11,14,17,18,25,26]. Moreover, related
studies have shed light on the understanding of the nature
of some monogenic diseases that are observed in males
despite the lethality (i.e. Rett syndrome) [27]. Regardless
these achievements chromosomal mosaicism is still
poorly described phenomenon. The latter is acknowled-
ged to be related to technical problems encountered
during attempts to detect chromosomal mosaicism [4,5].
Addressing the technical side of molecular cytogenetic
analysis of somatic genome variations, one can come to
the rueful conclusion that current achievements in the
field are exiguously appreciated leading, thereby, to slow-
ing down the somatic genome variation research. Looking
at recent advances in interphase cytogenetics, it is to note
that powerful methodological basis for high-resolution
surveys of chromosomal mosaicism does exist [28]. Fortu-
nately, examples of such studies are present in the availa-
ble literature [6,11-13,15,17,28]. In this context, it is to
mention the development of a molecular cytogenetic
 technique (interphase chromosome-specific multicolor
 banding) providing for visualization of the whole inter-
phase chromosome in a cell [6,13,29], exemplified by Fig-
ure 1. Thus, researchers of somatic genome variation have
to pay attention to these molecular cytogenetic develop-
ments.

Since chromosomal mosaicism is more likely to manifest
as aneuploidy, it appears important to delineate the way
aneuploidy occurs during the ontogeny or "aneuploidiza-
tion pathway" (Figure 2). Current data suggest aneu-
ploidization to represent a process that accompanies

**Figure 1**
Aneuploidy in the fetal human brain. Interphase chromo-
some-specific multicolor banding (ICS-MCB) allowing bar-
coding painting of the whole chromosome 9 in its integrity;
from left to right: monosomy, disomy (normal chromosomal
complement) and trisomy (partially reproduced from Yurov
et al. [13], an open-access article distributed under the terms
of the Creative Commons Attribution License).
human development. Being a devastative condition, aneuploidy causes prenatal death and/or chromosomal syndromes associated with severe developmental delays hardly compatible with life [4]. The human central nervous system development depicts that aneuploidy should be cleared, unless a pathogenic condition is produced [13]. Therefore, an "antianeuploidization" process (see legend to Figure 2) does exist in human, which is required for a human conception to develop into a newborn and, subsequently, to develop through the postnatal period of life. However, "antianeuploidization" seems to slowdown during human aging probably associated with aging or tumorigenesis. The latter is supported by current concepts in cancer and aging research [14,30]. The aneuploidization pathway seems, therefore, to be a kind of universal cascade of processes that leads to human disease, depending on the performance of the opposition processes, which we have arbitrarily called "antianeuploidization". Contrariwise, a balance between aneuploidization and "antianeuploidization" provides human organism to develop normally unless the "antianeuploidization" will slow down (Figure 2). We suggest that aneuploidization of a tissue should be the key process to produce the dysfunction. Being confined to the specific cell population, it probably causes tumorigenesis, whereas the whole tissue affected by aneuploidy should degenerate. This is partially supported by the data on brain diseases [4,12,25]. Notwithstanding, such attracting hypotheses concerning aneuploidization, that assume chromosomal mosaicism to be associated with human diseases, are to be tested.

The report that has inspired this communication addresses basic side of chromosome mosaicism research. However, Molecular Cytogenetics has published a series of original researches, which have paid attention to practical side of chromosomal mosaicism [31-36]. These have demonstrated that chromosomal mosaicism is an appreciable phenomenon frequently encountered in small supernumerary marker chromosomes (sSMC) research [31-33,35]. Furthermore, it provided evidences that mosaic structural chromosome rearrangements are likely to occur more frequently, than previously recognized [4,5,34,36]. In the light of studying sSMC, it should be additionally mentioned that chromosomal mosaicism could be cryptic [37,38] and dynamic [39]. The former is referred to as occurrence of more complex mosaics than revealed after karyotyping [37]. The latter is the occurrence of new genetic imbalances from an already abnormal cell or mosaicism resulting from behavioral peculiarities of a rearranged chromosome [39]. These two

Table 2: The load of chromosomal mosaicism to human prenatal mortality and postnatal morbidity

| Condition/disease | Description | References |
|-------------------|-------------|------------|
| Spontaneous abortions | ~25% of all spontaneous abortions (~50% of spontaneous abortions with chromosome abnormalities) exhibit chromosomal mosaicism | [17] |
| Chromosomal syndromes | 3–18% (depending on chromosome) | [4,5,7] |
| Mental retardation and/or multiple congenital malformation | ~3.5% in institutionalized children | Vorsanova & Yurov, unpublished observations |
| Autism | 16% in children with autism (~10% X chromosome aneuploidy in male children) | [11] |
| Schizophrenia | Mosaic aneuploidy of chromosomes 1, 18 and X in cells of the schizophrenia brain; mosaic X chromosome aneuploidy in blood lymphocytes | [7,8,12] |
| Autoimmune diseases | Monosomy of chromosome X in systemic sclerosis (6.2% of cells) and autoimmune thyroid disease (4.3% of cells) | [10] |
| Alzheimer disease | over 10% in brain cells; increase of aneuploidy of chromosome 21 in mitotic cells (skin fibroblasts or blood lymphocytes) | [25,26] |
| Meiotic aneuploidy | Chromosomal mosaicism confined to fetal ovarian tissues has potential to result into meiotic aneuploidy in conceptions | [15] |
types of chromosomal mosaicism require the application of high-resolution molecular cytogenetic techniques, i.e. subcenM-FISH or multicolor banding (MCB) [37-39]. This takes us back to the technical side of chromosome mosaicism detection and forces to conclude again that studying chromosomal mosaicism without taking into account new molecular cytogenetic techniques is almost useless. Here, it is to mention high-resolution genome screening approaches based on array-CGH. Such molecular cytogenetic techniques are extremely powerful for delineation of chromosomal breakpoints, identification of new microdeletion syndromes, and uncovering genomic variations in health and disease [7]. Related possibilities have made array-CGH-based techniques almost the most popular ones in current medical genetics. However, related approaches are poorly inapplicable (or even completely inapplicable) for uncovering low-level, cryptic and dynamic mosaicism. Therefore, genome screens by array-CGH miss cases of chromosomal mosaicism. This point should to be considered by researchers who plan to study this type of intercellular (somatic) genomic variations, as well.

Finishing our overview of chromosomal mosaicism in the light of the latest biomedical achievements, it is to highlight several points: (i) intercellular variations manifest-
ing as chromosomal mosaicism are likely to be involved in the genetic diversity; (ii) significant proportion of human pathogenic conditions are associated with chromosomal mosaicism; (iii) chromosomal mosaicism is still underrated biomedically a phenomenon that requires additional evaluations; (iv) current molecular cytogenetics possesses sufficiently powerful tools for uncovering the role of chromosomal mosaicism. Together, it suggests future biomedical research to involve studies of chromosomal mosaicism, which have the potential to give us new insights into pathobiology of human diseases and to help our understanding of the intercellular genomic variations.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

IYI wrote the manuscript and SGV and YBY contributed significant editorial input and original ideas.

Acknowledgements

This communication is partially inspired by original ideas of Dr. Ilia V Soloviev to whom the article is dedicated. Authors are supported by Philip Morris USA Inc.

References

1. Rieger R, Michaelis A, Green MM: Glossary of genetics and cytogenetics: classical and molecular 4th edition. Berlin – Heidelberg: Springer-Verlag (VEB Gustav Fischer Verlag Jena); 1976.

2. Schizel A: Catalogue of Unbalanced Chromosome Aberrations in Man 2nd edition. Berlin, New York: de Gruyter; 2001.

3. Yurov YV, Iourov IY, Monakhov VV, Soloviev IV, Vostrikov VM, Vorsanova SG: The variation of aneuploidy frequency in the developing and adult human brain revealed by an interphase FISH study. J Histochim Cytochem 2005, 53:385-390.

4. Iourov IY, Vorsanova SG, Yurov YB: Chromosomal variations in mammalian neuronal cells: known facts and attractive hypotheses. Int Rev Cytol 2006, 249:143-191.

5. Iourov IY, Vorsanova SG, Yurov YB: Intercellular genomic (chromosomal) variations resulting in somatic mosaicism: mechanisms and consequences. Curr Genomics 2006, 7:435-446.

6. Iourov IY, Liehr T, Vorsanova SG, Kolotii AD, Yurov YB: Visualization of interphase chromosomes in postmitotic cells of the human brain by multicolour banding (MCB). Chromosome Res 2006, 14:223-229.

7. Iourov IY, Vorsanova SG, Yurov YB: Molecular cytogenetics and cytogenomics of brain diseases. Curr Genomics 2008, 9:452-465.

8. Yurov YB, Vostrikov VM, Vorsanova SG, Monakhov VV, Iourov IY: Multicolor fluorescence in situ hybridization on postmortem brain in schizophrenia as an approach for identification of low-level chromosomal aneuploidy in neuropsychiatric diseases. Brain Dev 2001, 23(Suppl 1):186-190.

9. Youssoufian H, Pyentz RE: Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet 2002, 3:748-758.

10. Invernizzi P, Miozzo M, Selmi C, Persani L, Battezzati PM, Zini M, Luikki S, Meroni PL, Marasini B, Zeni S, Watnik M, Grati FR, Simonin G, Gerwiolin M, Podda M: X chromosome monosomy: a common mechanism of autoimmune diseases. J Immunol 2005, 175:575-578.

11. Yurov YV, Vorsanova SG, Iourov IY, Demidova IA, Beresheva AK, Kravetz VS, Monakhov VV, Kolotii AD, Voinova-Ulas VY, Gorbachevskaya NL: Unexplained autism is frequently associated with low-level mosaic aneuploidy. J Med Genet 2007, 44:521-535.

12. Yurov YV, Iourov IY, Vorsanova SG, Demidova IA, Kravetz VS, Beresheva AK, Kolotii AD, Monakhov VV, Urana NA, Vostrikov VM, Soloviev IV, Liehr T: The schizophrenia brain exhibits low-level aneuploidy involving chromosome 1. Schizophr Res 2008, 99:137-147.

13. Yurov YV, Iourov IY, Vorsanova SG, Liehr T, Kolotii AD, Kutsev SI, Pellerst F, Beresheva AK, Demidova IA, Kravets VS, Monakhov VV, Soloviev IV: Aneuploidy and confined chromosomal mosaicism in the developing human brain. PLoS ONE 2007, 2:e5558.

14. Russel LM, Strike P, Bari M, Jacobs PA: X chromosome loss and aging. Cytogenet Genome Res 2007, 116:181-185.

15. Hulten MA, Patel SD, Tankanovana M, Westgren M, Papadogianakis N, Johnson AM, Irwasson E: On the origin of trisomy 21 Down syndrome. Mol Cytogenet 2008, 1:21.

16. Giusskov T, Hall H, Hunt P: The origin of human aneuploidy: where we have been, where we are going. Hum Mol Genet 2007, 16(Spec No. 2):R23-R208.

17. Vorsanova SG, Kolotii AD, Iourov IY, Monakhov VV, Kirillova EA, Soloviev IV, Yurov YB: Evidence for high frequency of chromosomal mosaicism in sperm revealed by interphase FISH analysis. J Histochim Cytochem 2005, 53:375-380.

18. Kalousek DK, Dill FJ: Chromosomal mosaicism confined to the placenta in human conceptions. Science 1983, 211:665-667.

19. Pellestor F, Andreo B, Anahory T, Hamamah S: Low-level chromosomal aneuploidy in neuropsychiatric disorders. J Histochem Cytochem 2006, 54:167-179.

20. Luetjens CM, Rolf C, Gassner P, Werny JE, Nieszlag E: Sperm aneuploidy rates in younger and older man. Hum Reprod 2002, 17:1826-1832.

21. Stetten G, Escalon CS, South ST, McMichael JL, Saul DO, Blakemore KJ: Reevaluating confined placental mosaicism. Am J Med Genet 2004, 131:232-239.

22. Geigl JB, Langer S, Barwisch S, Pfleghaar K, Lederer G, Speicher MR: Analysis of gene expression patterns and chromosomal changes associated with aging. Cancer Res 2004, 64:8850-8857.

23. Wilkens L, Flemming P, Gebel M, Bleck J, Terkamp C, Wingen L, Kreipe H, Schelgerber B: Induction of aneuploidy by increasing chromosomal instability during differentiation of hepatocellular carcinoma. Proc Natl Acad Sci USA 2004, 101:1309-1314.

24. Leach NT, Rehder D, Jensen K, Holt S, Jackson-Cook C: Human chromosomes with shorter telomeres and large heterochromatin regions have a higher frequency of acquired somatic changes associated with age. Cancer Res 2004, 64:535-537.

25. Moros B, Marowski M, Mitag A, Lenz D, Tarnok A, Arensd T: Aneuploidy and DNA replication in the normal human brain and Alzheimer’s disease. J Neurosci 2007, 27:6859-6867.

26. Geller LN, Potter H: Chromosome missegregation and trisomy 21 mosaicism in Alzheimer’s disease. Neurobiol Dis 1999, 6:167-179.

27. Vorsanova SG, Yurov YB, Ulas YY, Demidova IA, Kolotii AD, Gorbachevskaya NL, Beresheva AK, Soloviev IV: Cytogenetic and molecular-cytogenetic studies of Rett syndrome (RTT): a retrospective analysis of a Russian cohort of RTT patients (the investigation of 57 girls and three boys). Brain Dev 2001, 23(Suppl 1):196-201.

28. Iourov IY, Vorsanova SG, Soloviev IV, Yurov YB: Interphase FISH: detection of intercellular genomic variations and somatic chromosomal mosaicism. In Fluorescence in situ hybridization (FISH) – Application guide Edited by: Liehr T. Berlin, Heidelberg: Springer-Verlag; 2009:301-311.

29. Iourov IY, Liehr T, Vorsanova SG, Yurov YB: Interphase chromosomal mosaicism confined to the X chromosome. Mol Cytogenet 2008, 1:26 http://www.molecularcytogenetics.org/content/1/1/26
and der(X)del(X)(p11.23)dup(X)(p11.21p11.22) provides insight into the possible mechanism of rearrangement. Mol Cytogenet 2008, 1:16.

34. Halder A, Jain M, Kabra M, Gupta N: Mosaic 22q11.2 microdeletion syndrome: diagnosis and clinical manifestations of two cases. Mol Cytogenet 2008, 1:18.

35. Murthy SK, Malhotra AK, Jacob PS, Naveed S, Al-Rowaished EEM, Mani S, Padariyakam S, Pramathan R, Nath R, Al-Ali MT, Al-Gazali L: Analphoid supernumerary marker chromosome characterized by aCGH and FISH as inv dup(3)(q25.33qter) de novo in a child with dysmorphic features and streaky pigmentation: case report. Mol Cytogenet 2008, 1:19.

36. Manolakos E, Kosyakova N, Thomaidis L, Neroutsou R, Weise A, Mihalatos M, Orru S, Kokotas H, Kitsos G, Liehr T, Petersen M: Complex chromosome rearrangement in a child with microcephaly, dysmorphic facial features and mosaicism for a terminal deletion del(1B)(q21.32-qter) investigated by FISH and array-CGH. Mol Cytogenet 2008, 1:24.

37. Fickelscher I, Stark H, Schulze E, Ernst G, Kosyakova N, Mkrtchyan H, MacDermont K, Sebire N, Liehr T: A further case with a small supernumerary marker chromosome (sSMC) derived from chromosome 1 – evidence for high variability in mosaicism in different tissues of sSMC carriers. Prenat Diagn 2007, 27:783-5.

38. Santos M, Mrasek K, Rigola MA, Starke H, Liehr T, Fuster C: Identification of a "cryptic mosaicism" involving at least four different small supernumerary marker chromosomes derived from chromosome 9 in a woman without reproductive success. Fertil Steril 2007, 88:969. e11–e17.

39. Iourov IY, Vorsanova SG, Liehr T, Monakhov VV, Soloviev IV, Yurov YB: Dynamic mosaicism manifesting as loss, gain and rearrangement of an isodicentric Y chromosome in a male child with growth retardation and abnormal external genitalia. Cytogenet Genome Res 2008, 121:302-306.